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Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated
with highmortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in
a real-world scenario and to deﬁne the predictors of the choice of echinocandins or azoles in IAC episodes.
Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four
countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011e2013). IAC was identiﬁed in 481 pa-
tients, 323 of whom received antifungal therapy (classiﬁed as the treatment group). After excluding 13
patients given amphotericin B, the treatment group was further divided into the echinocandin group (209
patients; 64.7%) and the azole group (101patients; 32.3%).MedianAPACHE II scoreswere signiﬁcantly higher
in the echinocandin group (p 0.013), but IAT did not differ signiﬁcantly with regard to the Candida species
involved. Logisticmultivariate stepwise regression analysis, adjusted for centre effect, identiﬁed septic shock
(adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as
the top three independent variables associated with an empirical echinocandin regimen. No differences in
30-day mortality were observed between groups. Echinocandin regimen was the ﬁrst choice for IAT in pa-
tients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins
were administered to patients with more severe disease. Some disagreements were identiﬁed between
current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational
measures are required to optimize therapies. L. Lagunes, CMI 2016;▪:1
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Department, Vall d'Hebron
Barcelona, Spain.
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Candida is the third most frequently isolated pathogen in criti-
cally ill patients [1]. Intraabdominal candidiasis (IAC) is the second
most frequent form of invasive candidiasis after bloodstream
infection, and it has been associated with high mortality rates of
between 25% and 40% [2e6]. The recovery of Candida from the
abdominal cavity has a worse prognosis in patients with peritonitis
[7,8]. The clinical criteria for deﬁning IAC are not speciﬁc, although a
recent European consensus of experts shortened the deﬁnition of
an IAC episode [9]. International guidelines focus mostly on can-
didaemia and make little reference to antifungal therapy for IAC
[10e12]. Delay in the initiation of treatment for invasive candidiasis
has been associatedwith increasedmortality [13e15]. Recently, in a
large multinational multicentre study carried out by our group
focusing only on IAC cases [16] the high mortality rate obtained
(~27%) underlined the importance of source control in patients
with IAC and septic shock. It remains unclear which patients should
receive empirical treatment, and which patients are at the highest
risk for developing invasive candidiasis. According to current
guidelines, appropriate treatment is based on azoles, polyenes or
echinocandins; however, the differences between these groups in
the treatment of IAC have not been assessed.
The objective of this secondary analysis is to identify current
practice in initial antifungal treatment (IAT) of IAC episodes in a
‘real-world scenario’ and to deﬁne the predictors of the choice of
one or another antifungal.
Materials and methods
Multinational multicentre retrospective cohort study conducted
at 13 teaching hospitals in four countries (Italy, Greece, Spain and
Brazil), over a 3-year period (2011e2013). All cases were recorded
continuously. Informed consent was waived and approved at each
participating centre ethics committee due to the observational
characteristics of the study. An episode of IAC was deﬁned ac-
cording to the 2013 European consensus [9], as follows:
(a) Candida detection by direct microscopy examination or
growth in culture from purulent or necrotic intraabdominal
specimens obtained during surgery or by percutaneous
aspiration
(b) Candida growth from bile, intra-biliary duct devices and bi-
opsy of intraabdominal organs
(c) Candida growth from blood cultures in a clinical setting of
secondary and tertiary peritonitis in absence of any other
pathogen and
(d) Candida growth from drainage tubes only if placed less than
24 h before the cultures.
Patients' demographic characteristics and infection-related
variables were collected from hospital medical records, microbi-
ology and pharmacy databases. Demographic data included age,
gender, co-morbidities, immunosuppressive agents, Acute Physi-
ology and Chronic Health Evaluation (APACHE II) score measured
within the ﬁrst 24 h of culture positivity, and intra-hospital location
at the time of diagnosis. Infection-related variables included source
of infection, Candida species, prior antibiotic exposure (>7 days in
the past 30 days), time to initiation of antifungal therapy, and type
of antifungal therapy. Adequate abdominal source control was
deﬁned as:
(a) Drainage of infected ﬂuid collections
(b) Debridement of infected tissue and the removal of devices or
foreign bodies andPlease cite this article in press as: Lagunes L, et al., Predictors of choice o
Microbiology and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2016.0(c) Deﬁnitive measures to correct anatomic derangements
resulting in ongoing microbial contamination and to restore
optimal function within 48 h of IAC diagnosis.
Treatment was considered adequate when the causative organ-
ism was ultimately shown to be susceptible. The following anti-
fungal doses were considered adequate: (a) ﬂuconazole 800 mg
loading dose (for obese patients body mass index >30 kg/m2:
1200e1600 mg) followed by a daily dose of at least 400 mg
(600e800 mg for patients with body mass index >30 kg/m2), (b)
caspofungin 70 mg loading dose (100 mg in obese) followed by 50
mg/day (80 mg/day), (c) micafungin 100 mg/day, and (d) anidula-
fungin 200 mg loading dose followed by 100 mg/day. Candida spe-
cies were isolated using the BACTEC 860 system (BectoneDickinson
Inc., Sparks, MD, USA) and BacT/Alert 3D (BioMerieux, Marcy
l'Etoile, France). The specieswere identiﬁed using API ID 32C system
(BioMerieux) or Vitek 2 system (BioMerieux). If both systems pro-
duced inconclusive results, isolates were deﬁnitively identiﬁed us-
ing supplemental tests, e.g. the presence or absence of well-formed
pseudohyphae on cornmealeTween 80 agar and growth at
42e45C. The last test was also required to differentiate isolates of
Candida albicans from those of Candida dubliniensis. Antifungal
susceptibility testing for caspofungin, anidulafungin, micafungin,
ﬂuconazole, itraconazole and voriconazolewas performedusing the
Sensititre YeasOne colorimetric plate (Trek Diagnostics Systems,
Cleveland, OH, USA) or by agar diffusion using E-test strips (Bio-
Merieux) and interpreted using CLSI breakpoints.
Population
Patients who received any antifungal were included in the
treatment group. Those that did not receive treatment were
excluded. Treated patients depending on IAT were further sub-
divided and assigned to echinocandin and azole groups; those who
received amphotericin as IAT were excluded to safeguard the sta-
bility of the model due to the low proportion of cases (Fig. 1).
Statistical analysis
All tests of signiﬁcancewere two-tailed and p values0.05 were
considered statistically signiﬁcant. Continuous variables were
compared by the Student t test or analysis of variance for normally
distributed variables and the ManneWhitney U test or Krus-
kaleWallis test for non-normally distributed variables. The chi-
square or Fisher's exact test was used to compare categorical var-
iables. Values were expressed as medians (25e75th centile)
(continuous variables) or as a frequency of the group from which
they were derived (categorical variables).
Multivariate stepwise analysis was performed, with initial
antifungal treatment as the dependent outcome variable, and 0.05
was set as the limit for the acceptance or removal of new terms. All
covariates that were statistically signiﬁcant at 0.05 in the univariate
analysis (see Supplementary material, Table S1) were included in
the model. The model was adjusted to assess a possible centre in-
ﬂuence, by stratiﬁcation of cases at each centre that ensured a non-
different distribution among them. Estimations were carried out at
each stratum (centre) [18] and results are expressed as adjusted OR
(aOR). Statistics were performed using SPSS, version 21.0 for Win-
dows (SPSS, Inc., Chicago, IL, USA) and R commander (Fox, 2005),
version 0.999375-38.
Results
In this 3-year period, 481 cases of IAC were recorded and
included in the analysis. In all, 323 patients received antifungalf initial antifungal treatment in intraabdominal candidiasis, Clinical
6.005
Fig. 1. Total population and treatment group, Echinocandin versus azole group; after
exclusion of no treated patients and those who received amphotericin.
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(64.7%) received an echinocandin as IAT, 101 (32.3%) received an
azole and 13 (4%) received amphotericin B. Table 1 summarizes the
clinical characteristics of the treatment group. Males more
frequently received azoles for IAC than echinocandins (69/101
(68.3%) versus 107/209 (51.2%) respectively, p 0.004). APACHE II
score was higher in the echinocandin group (median 17, inter-
quartile range 25%e75% 11e21) than in the azole group (median 16,
interquartile range 25%e75% 8e20, p 0.013). Regarding infection
types, patients with secondary peritonitis were more likely to
receive echinocandins than azoles (44.7% versus 26.8%, p 0.001).
Patients in the surgical ward at time of diagnosis more frequently
received echinocandins (55% versus 37%, p 0.002); there were no
differences associated with other wards. Patients with septic shock
at the time of diagnosis more frequently received an echinocandin
regimen (52.3% versus 39.6%, p 0.031). In contrast, patients with
candidaemia and those with previous Candida colonization more
frequently received an azole (27.3% versus 13.4%, p 0.003 and 40.4%
versus 24.9%, p 0.006; respectively) (Table 2). Adequacy of treat-
ment did not differ signiﬁcantly (echinocandin group 84.7%, azole
group 85.7%, p 0.91). IAT was not affected by the type of Candida
species, and no difference in 30-day mortality was observed be-
tween groups (Table 3).
There was no statistical association between the prescription of
antifungal therapy and the year when the IAC episode was recor-
ded. Echinocandins were the most frequent IAT prescribed across
the study period, followed by azoles (67.4% versus 32.6%, p 0.64).
Differences in IAT according to geographical area zone are shown in
the Supplementary material (Table S2).
In adjusted multivariate analysis stratiﬁed for the centre effect,
the top three risk factors for prescription of an echinocandin were
septic shock (aOR 1.54, 95% CI 0.88e2.70), surgical ward (aOR 1.16,Please cite this article in press as: Lagunes L, et al., Predictors of choice o
Microbiology and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2016.095% CI 0.62e2.19) and APACHE II score >15 (aOR 1.16, 95% CI
0.71e1.90). Azoles were more often prescribed in patients with
previous Candida colonization (OR for echinocandin 0.57, 95% CI
0.32e1.00 p 0.053) and candidaemia (OR for echinocandin 0.54,
95% CI 0.28e1.04, p 0.068) though the differences were not sta-
tistically signiﬁcant (Table 4).
Discussion
Patients with higher severity scores and septic shock at the time
of diagnosis more frequently received an echinocandin as IAT,
whereas a trend favouring azoles was identiﬁed in the presence of
candidaemia or prior azole exposure.
As in a previous study [9] the proportion of patients with both
IAC and candidaemia was about 15%, raising concerns on general-
ization of recommendations to non-candidaemic patients. The time
required to have positivity for Candida sp. in blood cultures and the
fact that only half of the cultures are positive in candidaemia make
it difﬁcult to initiate prompt, correct antifungal treatment. The
reference standard for IAC diagnosis is the sterile collection of
cultures from infected tissues; however, the procedures involved
are invasive andmay lead to unnecessary risks in unstable patients.
In recent years, fungal biomarkers have emerged as promising tools
in culture-negative subjects [19] for identifying patients at high risk
of developing an IAC episode who are likely to beneﬁt from early
initiation and correct treatment [20,21].
The differentiation between contamination and infection when
Candida is recovered from intraabdominal samples is currently
under debate, but in any case the presence of this pathogen has
been associated with poor prognosis [7,8]. Recently, an expert Eu-
ropean consensus attempted to redeﬁne IAC [9], and a subsequent
report showed a high mortality associated with this condition [16].
In this scenario, the selection of a particular antifungal must include
a number of factors: the host, the clinical situation at diagnosis, and
treatment-related variables such as recent exposure to an anti-
fungal agent, allergies, potential drug interactions, local epidemi-
ology and resistance. Many of these variables were recorded and
analysed in the present study. The impact of treatment on the
outcome of patients with invasive candidiasis has been widely
assessed, and delay and inadequacy of treatment have been asso-
ciated with poor outcome [13e17]; however, most previous ran-
domized control trials assessed primarily bloodstream infection
due to Candida spp [22,23].
According to current Infectious Diseases Society of America and
ESCMID guidelines, patients with invasive candidiasis must receive
prompt, adequate treatment, and the decision should be based on
the patient's clinical situation. It is strongly recommended that
treatment with an echinocandin be initiated when septic shock,
haemodynamic instability or high risk for an azole-resistant causal
agent is suspected or present [10,11]. Among our patients with
candidaemia, there was a non-signiﬁcant trend towards the use of
an azole regimen as IAT. Our analysis identiﬁed septic shock as an
independent determinant for receiving an echinocandin-based
regimen as IAT for IAC, in accordance with these guidelines, and
observed a tendency to use it in patients with higher severity scores
at diagnosis, but we did not ﬁnd in IAC an association of echino-
candin with previous azole exposure.
In the light of what is known, some studies have reported an
increase in azole-resistant species when azole exposure is docu-
mented [24,25] and azole use under these conditions is not rec-
ommended. Interestingly, we observed a non-signiﬁcant trend
toward the use of an azole as IAT for IAC in cases of previous azole
exposure and its use was safe. However, the incidence of resistance
to ﬂuconazole in our population remains relatively low (around
18.3%), whereas susceptibility of therapy in the azole groupf initial antifungal treatment in intraabdominal candidiasis, Clinical
6.005
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Age median (IQR) 63 (53e75) 63 (53e75) 61 (49e73) 60 (49e67) <0.001 0.590
Male 182 (56.3) 107 (51.2) 69 (68.3) 9 (69.2) 0.011 0.004
APACHE II score median (IQR) 15 (9e20) 17 (11e21) 16 (8e20) 18 (15e23) 0.003 0.013
Dialysis 23 (7.1) 12 (5.8) 8 (7.9) 3 (23.1)
SOT 19 (5.8) 8 (3.8) 9 (8.9) 2 (15.4)
ESRD 24 (7.4) 18 (8.7) 5 (5) 1 (7.7)
Solid tumour 127 (39.3) 86 (41.1) 36 (35.4) 5 (38.5)
Haemato-malignancy 10 (3) 6 (2.4) 4 (4) d
Immunosuppression 54 (16.7) 33 (15.9) 16 (16) 5 (38.5)
Steroids 68 (21) 47 (22.6) 15 (15) 6 (46.3) 0.025 0.120
COPD 39 (12) 29 (13.9) 9 (8.9) 1 (7.7)
Heart disease 59 (18.2) 39 (18.8) 19 (19) 1 (7.7)
Type <0.001 0.053
Secondary peritonitis 121 (37.4) 93 (44.7) 26 (26.8) 2 (15.4) 0.001 0.001
Tertiary peritonitis 31 (9.6) 18 (8.7) 13 (13.4) d
Abdominal abscess 87 (26.9) 52 (25) 33 (34) 2 (15.4)
Pancreatitis 37 (11.4) 19 (9.1) 14 (14.4) 4 (30.8) 0.039 0.202
Biliary tract 35 (10.8) 23 (11.1) 9 (9.3) 3 (23.1)
Other 7 (2.1) 3 (1.4) 2 (2.1) 2 (15.4) 0.004 0.721
WARD 0.004 0.001
Internal medicine 26 (8) 17 (8.1) 7 (7) 2 (15.4)
Surgery ward 160 (49.5) 116 (55.5) 37 (37) 7 (53.8) 0.007 0.002
ICU 98 (30.3) 61 (29.2) 34 (34) 3 (23.1) 0.611 0.423
Haemato-oncology 6 (1.8) 3 (1.2) 2 (2) 1 (7.4)
SOT ward 3 (0.1) 2 (1) 1 (1) d
Other 29 (8.9) 10 (4.8) 19 (19) d <0.001 <0.001
Abdominal surgery 246 (76.1) 152 (72.7) 82 (81.2) 12 (92.3) 0.099 0.105
Reoperation 148 (45.8) 101 (48.3) 44 (43.6) 3 (23.1)
Gastrointestinal perforation 71 (21.9) 49 (23.6) 20 (19.8) 2 (15.4)
Anastomotic leak 72 (22.3) 45 (21.5) 25 (24.8) 2 (15.4)
CVC 251 (77.7) 173 (82.8) 69 (68.3) 9 (69.2) 0.012 0.004
TPN 209 (64.7) 142 (67.9) 58 (58) 9 (69.2) 0.218 0.087
AB >7days 262 (81.1) 166 (79.4) 83 (82.2) 13 (100) 0.175 0.568
Prior azole exposure 54 (16.7) 24 (11.5) 23 (22.8) 7 (53.8) <0.001 0.009
Prior Candida colonization 95 (29.1) 48 (24.9) 40 (40.4) 4 (30.8) 0.024 0.006
Candidaemia 63 (19.5) 27 (13.4) 27 (27.3) 9 (69.2) <0.001 0.003
Septic shock 157 (48.6) 110 (52.3) 40 (39.6) 7 (53.8) 0.092 0.031
Vasopressor 154 (47.6) 106 (50.7) 42 (41.6) 6 (46.2) 0.318 0.131
Concomitant bacteria 217 (67.1) 148 (71.2) 64 (64) 5 (38.5) 0.033 0.204
Adequate source control 198 (61.3) 134 (64.1) 64 (64.6)
CASPO S 280 (86.6) 194 (98) 77 (98.7) 9 (75) <0.001 0.679
FLUCO S 223 (69) 154 (83.2) 60 (77.9) 9 (75) 0.042 0.012
Abbreviations: IQR, interquartile range; SOT, solid organ transplant; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit;
CVC, central venous catheter; TPN, total parenteral nutrition; CASPO, caspofungin; FLUCO, ﬂuconazole; AB>7days, antibiotics previously received for more than 7 days.
a p value for echinocandin versus ﬂuconazole versus amphotericin B.
b p value for echinocandin versus ﬂuconazole.
L. Lagunes et al. / Clinical Microbiology and Infection xxx (2016) 1e64remained high (85.7%). This is consistent with a recent multicentre
cohort study of Candida glabrata bloodstream infection in Spain
[26] ﬂuconazole use was not associated with unfavourable evolu-
tion (aOR for 14-day mortality 1.16, 95% CI 0.22e6.17; aOR for
treatment failure 0.83, 95% CI 0.27e2.61) when compared with
echinocandins or liposomal amphotericin B regimens, due to the
lower incidence of resistance of C. glabrata to azoles in southern
Europe when compared with America.
Mortality in patients with inadequate IAT was around 48% [9].
In our cohort, there were no differences between echinocandin
and azole regimens on outcomes. Similarly, we could not identify
associations between antifungal class and Candida species
causing IAC, even in species with lower reported susceptibility to
echinocandins such as Candida parapsilosis complex. Recent data
show that the echinocandin regimen does not negatively inﬂu-
ence outcome in candidaemia due to C. parapsilosis [27]. Echi-
nocandins have been associated with better outcomes in
previous reviews [28], but in these cohorts only around 1% of
cases were IAC.
Some limitations of our analysis should be acknowledged. First
we were only able to analyse the data recorded; for instance, wePlease cite this article in press as: Lagunes L, et al., Predictors of choice o
Microbiology and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2016.0were unable to record the proportion of patients later transferred to
the intensive care unit. Whether certain centres used predictive
rules to initiate antifungal therapy remains unknown. Prescription
of echinocandin shows a high diversity in different sites, being a
limitation and precluding analysis of prognosis. Therefore, the
model was adjusted to assess a possible centre effect. Finally there
were certain differences according to geographical area, probably
due to local ecology, drug interactions, or the fact that either
external infectious disease consultants or critical care staff took
decisions on antifungal therapy; this may explain the relation be-
tween presence in the surgical ward at diagnosis and echinocandin
use [29].
Our ﬁndings have implications for future research and future
practice. This large multinational multicentre analysis represents a
real-life scenario and reﬂects the decision process when choosing
one or another antifungal. Indeed, our study suggests that pre-
scription of antifungals for IAC at the bedside does not conform to
clinical practice guidelines (e.g. use of ﬂuconazole in the presence of
C. glabrata or previous azole exposure); therefore, further dissem-
ination and educational measures are required to use therapies
concordant with guidelines.f initial antifungal treatment in intraabdominal candidiasis, Clinical
6.005
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Male 176 (56.8) 107 (51.2) 69 (68.3) 0.004
Age 63 (53e75) 63 (53e75) 61 (49e73) 0.59
APACHE II score diagnosis 15 (9e20) 17 (11e21) 16 (8e20) 0.013
Dialysis 20 (6.5) 12 (5.8) 8 (7.9) 0.471
SOT 17 (5.5) 8 (3.8) 9 (8.9) 0.067
ESRD 23 (7.4) 18 (8.7) 5 (5) 0.245
Solid tumour 122 (39.4) 86 (41.1) 36 (35.4) 0.352
Haemato malignancy 10 (3.2) 6 (2.4) 4 (4) 0.611
Immunosuppressant 49 (15.8) 33 (15.9) 16 (16) 0.976
Steroids 62 (20) 47 (22.6) 15 (15) 0.12
COPD 38 (12.3) 29 (13.9) 9 (8.9) 0.212
Heart disease 58 (18.7) 39 (18.8) 19 (19) 0.958
Type of IAC 0.053
Secondary peritonitis 119 (39) 93 (44.7) 26 (26.8) 0.001
Tertiary peritonitis 31 (10.2) 18 (8.7) 13 (13.4) 0.241
Abdominal abscess 85 (27.9) 52 (25) 33 (34) 0.149
Pancreatitis 33 (10.8) 19 (9.1) 14 (14.4) 0.202
Biliary tract 32 (10.5) 23 (11.1) 9 (9.3) 0.57
Other 5 (1.6) 3 (1.4) 2 (2.1) 0.721
WARD 0.001
Internal medicine 24 (7.7) 17 (8.1) 7 (7) 0.71
Surgery ward 153 (49.4) 116 (55.5) 37 (37) 0.002
ICU 95 (30.6) 61 (29.2) 34 (34) 0.423
Haemato-oncology 5 (1.6) 3 (1.2) 2 (2) 0.721
SOT ward 3 (1.0) 2 (1) 1 (1) 0.97
Previous abdominal
surgery
234 (75.5) 152 (72.7) 82 (81.2) 0.105
Reoperation 145 (46.8) 101 (48.3) 44 (43.6) 0.431
Gastrointestinal
perforation
69 (22.3) 49 (23.6) 20 (19.8) 0.457
Anastomotic leak 100 (21.4) 45 (21.5) 25 (24.8) 0.528
CVC 242 (78.1) 173 (82.8) 69 (68.3) 0.004
TPN 200 (65.5) 142 (67.9) 58 (58) 0.087
AB >7days 340 (73) 166 (79.4) 83 (82.2) 0.568
Prior azole exposure 47 (15.2) 24 (11.5) 23 (22.8) 0.009
Prior Candida colonization 88 (28.4) 48 (24.9) 40 (40.4) 0.006
Candidaemia 54 (17.4) 27 (13.4) 27 (27.3) 0.003
Septic shock 150 (48.4) 110 (52.3) 40 (39.6) 0.031
Concomitant bacteria 212 (68.4) 148 (71.2) 64 (64) 0.204
Adequate source control 284 (61.2) 134 (64.1) 64 (64.6) 0.928
CASPO S 271 (87.4) 194 (98) 77 (98.7) 0.679
FLUCO S 214 (69) 154 (83.2) 60 (77.9) 0.012
Abbreviations: IQR, interquartile range; SOT, solid organ transplant; ESRD, end-
stage renal disease; COPD, chronic obstructive pulmonary disease; ICU, intensive
care unit; GI, gastrointestinal; CVC, central venous catheter; TPN, total parenteral
nutrition; CASPO, caspofungin; FLUCO, ﬂuconazole; AB >7 days, antibiotics previ-
ously received for more than 7 days.
Table 4
Variables selected by multivariate stepwise logistic regression for prediction of
choice for echinocandin versus azole therapy
Variable OR (95% CI) p value aOR (95% CI)
Prior Candida colonization 0.57 (0.32e1.00) 0.053 1.02 (0.35e2.39)
Septic shock 2.18 (1.25e3.82) 0.006 1.54 (0.88e2.70)
Candidaemia 0.54 (0.28e1.04) 0.068 0.78 (0.38e1.59)
Secondary peritonitis 1.73 (0.97e3.08) 0.062 0.92 (0.57e1.47)
Surgery ward 2.28 (1.30e3.99) 0.004 1.16 (0.62e2.19)
APACHE II score >15 1.54 (0.89e2.68) 0.118 1.16 (0.71e1.90)
Prior azole therapy 0.56 (0.27e1.15) 0.434 0.74 (0.37e1.148)
Included variables: APACHE II score >15, secondary peritonitis, surgery ward, cen-
tral venous catheter, male gender, previous azole exposure, previous Candida
colonization, septic shock, candidaemia.
aOR, adjusted OR for centre effect.
HosmereLemeshow goodness-of-ﬁt-test p 0.103.
L. Lagunes et al. / Clinical Microbiology and Infection xxx (2016) 1e6 5In an era of personalizedmedicine, therapeutic decisions should
be taken based on scores, phenotypes and biomarkers. Our ﬁndings
suggest that high severity scores and use of vasopressors are
important drivers for therapeutic decisions. Scores and prediction
rules have high sensitivity (but low speciﬁcity) and should be used
to identify patients at low risk [30]. Further epidemiologicalTable 3
Adequacy of treatment, microorganism and outcome between echinocandin or
azole as initial antifungal therapy, n (%)
All Echinocandin Azole p
Adequate antifungal 263 (84.8) 177 (84.7) 86 (85.7) 0.91
Candida species 0.37
C. albicans 206 (66.5) 145 (69.2) 61 (60.4) 0.12
C. glabrata 56 (18.1) 33 (15.8) 23 (22.8) 0.15
C. tropicalis 21 (6.8) 15 (7.2) 6 (5.9) 0.68
C. parapsilosis 17 (5.5) 9 (4.3) 8 (7.9) 0.19
C. krusei 7 (2.3) 5 (2.4) 2 (2) 0.81
Death 30 days 79 (25.5) 56 (26.9) 23 (22.8) 0.57
Please cite this article in press as: Lagunes L, et al., Predictors of choice o
Microbiology and Infection (2016), http://dx.doi.org/10.1016/j.cmi.2016.0research should be performed on prognostic factors for IAC with
homogeneous prescriptions, differences in IAC between surgical
wards and ICU hospitalization, as well as translational research on
genomics, proteomics and metabolomics.
Conclusions
Echinocandins were preferred as initial antifungal treatment in
patients with IAC and septic shock and in patients in surgical wards
at the time of diagnosis. No statistical difference in mortality was
observed between the two regimens in IAC episodes, even though
echinocandins were administered to patients with more severe
disease.
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